---
title: "TAZPOWER: Elamipretide Phase 2/3 Results | Primara Labs"
url: https://www.primaralabs.com/research/trials/tazpower
source: Primara Labs, markdown mirror of the HTML page
---

# TAZPOWER

In TAZPOWER, a phase 2/3 trial of elamipretide in males aged 12 and over with Barth syndrome (n=12), the double-blind crossover part did not show a statistically significant difference from placebo on either primary endpoint (ClinicalTrials.gov NCT03098797 (TAZPOWER)).

Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.

Updated 24 September 2026

## Results

The double-blind crossover part did not show a statistically significant difference from placebo on either primary endpoint.

## Side effects reported

TAZPOWER: The extension report names injection site reactions as the most commonly reported adverse event, without rates by arm.

Design

## Trial design and sources

Compound

Elamipretide

Phase

2/3

Population

Males aged 12 and over with Barth syndrome

Participants randomised

12

Duration

28 weeks

Primary endpoint

Six-minute walk test distance and the Barth Syndrome Symptom Assessment total fatigue score, in a placebo-controlled crossover of two 12-week periods

Estimand

Not stated in the source read

Read out

1 November 2020

Ten of the twelve participants continued into an open-label extension of up to 168 weeks with no placebo arm. The extension report names injection site reactions as the most commonly reported adverse event, without rates by arm.

-   ClinicalTrials.gov NCT03098797 (TAZPOWER) [open](https://clinicaltrials.gov/study/NCT03098797) · checked 3 November 2026
-   Thompson WR et al. Genet Med 2024 (TAZPOWER 168-week open-label extension), PubMed 38602181 [open](https://pubmed.ncbi.nlm.nih.gov/38602181/) · checked 3 November 2026
-   Registry: NCT03098797

Questions

## TAZPOWER, answered

### What did TAZPOWER find?

In TAZPOWER, a phase 2/3 trial of elamipretide in males aged 12 and over with Barth syndrome (n=12), the double-blind crossover part did not show a statistically significant difference from placebo on either primary endpoint (ClinicalTrials.gov NCT03098797 (TAZPOWER)).

### What side effects were reported in TAZPOWER?

TAZPOWER: The extension report names injection site reactions as the most commonly reported adverse event, without rates by arm.

Related

## More on elamipretide

-   [MMPOWER-3](https://www.primaralabs.com/research/trials/mmpower-3)
-   [Evidence Map: Elamipretide](https://www.primaralabs.com/research/evidence#elamipretide)
-   [SS-31 10mg](https://www.primaralabs.com/marketplace/ss-31)